Bupivacaine - Fruithy Holdings Limited
Alternative Names: HYR-PB21Latest Information Update: 28 Aug 2026
At a glance
- Originator Fruithy Holdings
- Class Amides; Anaesthetics; Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules; Xylenes
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers) in Australia (SC, Injection)
- 21 Jul 2026 Fruithy Holdings plans a phase I trial for Postoperative pain (In volunteers) in July 2026 (SC) (NCT07717086)
- 03 Mar 2020 Phase-I clinical trials in Postoperative pain (In volunteers) in Australia (SC) (NCT04169256)